DE69435022D1 - Kombination von Angiotensin-II antagonistisch wirkenden Benzimidazolen mit Diuretika - Google Patents

Kombination von Angiotensin-II antagonistisch wirkenden Benzimidazolen mit Diuretika

Info

Publication number
DE69435022D1
DE69435022D1 DE69435022T DE69435022T DE69435022D1 DE 69435022 D1 DE69435022 D1 DE 69435022D1 DE 69435022 T DE69435022 T DE 69435022T DE 69435022 T DE69435022 T DE 69435022T DE 69435022 D1 DE69435022 D1 DE 69435022D1
Authority
DE
Germany
Prior art keywords
sup
group
angiotensin
compound
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69435022T
Other languages
English (en)
Other versions
DE69435022T2 (de
Inventor
Yoshiyuki Inada
Keiji Kubo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15153791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69435022(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE69435022D1 publication Critical patent/DE69435022D1/de
Application granted granted Critical
Publication of DE69435022T2 publication Critical patent/DE69435022T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69435022T 1993-06-07 1994-06-07 Kombination von Angiotensin-II antagonistisch wirkenden Benzimidazolen mit Diuretika Expired - Lifetime DE69435022T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13552493 1993-06-07
JP13552493 1993-06-07

Publications (2)

Publication Number Publication Date
DE69435022D1 true DE69435022D1 (de) 2007-10-18
DE69435022T2 DE69435022T2 (de) 2008-05-29

Family

ID=15153791

Family Applications (4)

Application Number Title Priority Date Filing Date
DE69434560T Expired - Lifetime DE69434560T2 (de) 1993-06-07 1994-06-07 Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit Manidipin zur Behandlung von Bluthochdruck
DE69435021T Expired - Lifetime DE69435021T2 (de) 1993-06-07 1994-06-07 Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit einem Diuretikum
DE69435022T Expired - Lifetime DE69435022T2 (de) 1993-06-07 1994-06-07 Kombination von Angiotensin-II antagonistisch wirkenden Benzimidazolen mit Diuretika
DE69432644T Expired - Lifetime DE69432644T2 (de) 1993-06-07 1994-06-07 Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69434560T Expired - Lifetime DE69434560T2 (de) 1993-06-07 1994-06-07 Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit Manidipin zur Behandlung von Bluthochdruck
DE69435021T Expired - Lifetime DE69435021T2 (de) 1993-06-07 1994-06-07 Kombination eines Angiotensin-II antagonistisch wirkenden Benzimidazols mit einem Diuretikum

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69432644T Expired - Lifetime DE69432644T2 (de) 1993-06-07 1994-06-07 Kombination eines Angiotensin-II antagonistisch wirkendes Benzimidazols mit ein Diuretikum

Country Status (9)

Country Link
EP (6) EP0753301B1 (de)
AT (4) ATE372116T1 (de)
CA (1) CA2125251C (de)
CY (1) CY2370B1 (de)
DE (4) DE69434560T2 (de)
DK (1) DK0753301T3 (de)
ES (1) ES2193217T3 (de)
PT (1) PT753301E (de)
SG (1) SG45336A1 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995033456A2 (en) * 1994-06-07 1995-12-14 Telor Ophthalmic Pharmaceuticals, Inc. Reducing intraocular pressure using aryloxy- and aryl-acetic acids
US5763491A (en) * 1994-12-09 1998-06-09 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US6228873B1 (en) 1994-12-09 2001-05-08 The Regents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
GB2295966B (en) * 1994-12-14 1997-09-24 Bioglan Ireland Direct compression tablets
WO1996040256A1 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
JPH11507627A (ja) * 1995-06-07 1999-07-06 ジー．ディー．サール アンド カンパニー 充血性心不全症を処置するためのエポキシ−ステロイド系アルドステロン拮抗物質とアンギオテンシンｉｉ拮抗物質との組合せ治療
ATE216261T1 (de) * 1995-06-07 2002-05-15 Searle & Co Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist
RU2188013C2 (ru) * 1996-04-05 2002-08-27 Такеда Кемикал Индастриз, Лтд. Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность
AU8996698A (en) * 1997-09-10 1999-03-29 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
KR100550167B1 (ko) * 1998-07-10 2006-02-08 노파르티스 아게 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
AU2001227084A1 (en) * 2000-01-25 2001-08-07 Japan Tobacco Inc. N-arylhydrazide compounds and use thereof as drugs
US20040102502A1 (en) * 2000-10-25 2004-05-27 Toshifumi Watanabe Preventing/remedies for portal hypertension
JP2004514703A (ja) * 2000-12-01 2004-05-20 ノバルティス　アクチエンゲゼルシャフト 有機化合物の組合せ剤
AU2002349673A1 (en) * 2001-12-03 2003-06-17 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
CN1774251A (zh) 2001-12-12 2006-05-17 法玛西雅公司 应用环氧甾类醛固酮受体拮抗剂治疗眼病的方法
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
CA2514921C (en) * 2003-01-31 2013-04-30 Sankyo Company, Limited Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension
DE602004022284D1 (de) 2003-05-15 2009-09-10 Roskamp Res Llc Verfahren zur herstellung von medikamenten zur verringerung der amyloid-abscheidung, amyloid-neurotoxizität und mikrogliosis
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
PL2214666T3 (pl) 2007-10-05 2014-06-30 Alzheimers Inst Of America Inc Sposób ograniczania powstawania złogów amyloidu, neurotoksyczności amyloidu i mikroglejozy przez zastosowanie enancjomeru (-)-nilwadypiny
JP5635491B2 (ja) 2008-07-31 2014-12-03 武田薬品工業株式会社 固形医薬組成物
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
CN102481248B (zh) * 2009-04-30 2013-12-11 武田药品工业株式会社 固体制剂
TR201004754A1 (tr) * 2010-06-11 2012-01-23 Sanovel �La� San. Ve T�C. A.�. Yeni Farmasötik Kombinasyonlar
JP6231553B2 (ja) 2012-05-07 2017-11-15 バイエル ファーマ アクチエンゲゼルシャフト ニフェジピンおよびカンデサルタン・シレキセチルを含む医薬投与形を製造する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2016710A1 (en) * 1989-05-15 1990-11-15 Prasun K. Chakravarty Substituted benzimidazoles as angiotensin ii antagonists
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE69130192T2 (de) * 1990-06-08 1999-03-25 Hoechst Marion Roussel Inc Benzimidazol-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Anwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
FR2673427B1 (fr) * 1991-03-01 1993-06-18 Sanofi Elf Derives heterocycliques diazotes n-substitues par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them
TW300219B (de) * 1991-09-14 1997-03-11 Hoechst Ag
TW284688B (de) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
GB2270841A (en) * 1992-09-09 1994-03-30 Merck & Co Inc Compositions for Treating vascular restenosis
WO1994009778A1 (en) * 1992-10-26 1994-05-11 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
MX9603259A (es) * 1994-02-08 1997-03-29 Novartis Ag Tratamiento de glaucoma normotensivo con antagonistas de angiotensina ii.

Also Published As

Publication number Publication date
CA2125251C (en) 2005-04-26
PT753301E (pt) 2003-08-29
CY2370B1 (en) 2004-06-04
DK0753301T3 (da) 2003-07-21
EP0628313B1 (de) 2005-11-30
EP2277520A3 (de) 2011-08-24
EP0753301B1 (de) 2003-05-07
EP0753301A1 (de) 1997-01-15
EP1306089B1 (de) 2007-09-05
EP1306089A1 (de) 2003-05-02
EP2277520A2 (de) 2011-01-26
DE69435021T2 (de) 2008-05-29
EP1844774A3 (de) 2008-08-20
DE69432644T2 (de) 2003-11-27
ATE372116T1 (de) 2007-09-15
EP0628313A1 (de) 1994-12-14
ATE372115T1 (de) 2007-09-15
SG45336A1 (en) 1998-01-16
DE69434560D1 (de) 2006-01-05
DE69432644D1 (de) 2003-06-12
ATE311188T1 (de) 2005-12-15
CA2125251A1 (en) 1994-12-08
EP1844774A2 (de) 2007-10-17
ES2193217T3 (es) 2003-11-01
EP1306088B1 (de) 2007-09-05
DE69435022T2 (de) 2008-05-29
ATE239471T1 (de) 2003-05-15
DE69434560T2 (de) 2006-06-08
EP1306088A1 (de) 2003-05-02
DE69435021D1 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
ATE372116T1 (de) Kombination von angiotensin-ii antagonistisch wirkenden benzimidazolen mit diuretika
ES2065182T3 (es) Derivados de fenilamidinas utiles como inhibidores de la agregacion de plaquetas.
TR199701355A2 (xx) L�kozit adhasyonu inhibit�rleri olarak yeni heterosiklenler ve vla-4-antagonistleri.
ATE180773T1 (de) N-sulfonyl-2-oxoindol-derivate mit einer affinität für die vasopressin und/oder ocytocin rezeptoren
ATE253546T1 (de) Chalcon-derivate und medikamente die diese enthalten
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
TR199801782T2 (xx) Kinoksalindionlar
ATE142641T1 (de) Neue peptid-verbindungen und verfahren zur herstellung davon
GR3033862T3 (en) Angiotensin ii antagonists as a prophylactic or therapeutic drug for renal diseases.
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
DK0659193T3 (da) Blodpladeaggregationsinhibitorer
PE84299A1 (es) Compuestos policiclicos parcialmente hidrogenados
ES2116612T3 (es) Nuevas bis-naftalimidas para el tratamiento del cancer.
KR970703301A (ko) 신규 디아미노메틸리덴 유도체(novel diamincmethylidene derivative)
NO934760D0 (no) Arylsubstituerte heterosykliske forbindelser
ES2149193T3 (es) Compuestos heterociclicos sustituidos con alquilo.
ATE73795T1 (de) Thioformamid-derivate.
ES2049703T3 (es) Derivados sulfurados de acidos biliares.
FI873145A0 (fi) Nya tetracykliska indolderivat.
RU93045455A (ru) Производные пиперидина, способ их получения и фармацевтическая композиция на их основе

Legal Events

Date Code Title Description
8364 No opposition during term of opposition